UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma

Leukemia & lymphoma, 2015-03, Vol.56 (3), p.645-649

2015

Volltextzugriff (PDF)

Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single‐arm, phase 2 study

British journal of haematology, 2014-05, Vol.165 (4), p.510-518

2014

Volltextzugriff (PDF)

Modified Delphi panel consensus recommendations for management of severe aplastic anemia

Blood advances, 2024-08, Vol.8 (15), p.3946-3960

2024

Volltextzugriff (PDF)

Deconditioning after "Moving On" rehabilitation

Journal of clinical oncology, 2018-10, Vol.36 (30_suppl), p.291-291

Fanning, Suzanne R.

2018

Volltextzugriff (PDF)

We will not stop until the world dreams in cheese: Redefining the Wisconsin cheese brand

Journal of brand strategy, 2021-01, Vol.10 (1), p.26-35

Fanning, Suzanne

2021

Volltextzugriff (PDF)

Leveraging Virtual Reality to Enhance Expeditionary Medical Team Performance in Three Key Areas

Military medicine, 2020-09, Vol.185 (9-10), p.e1357-e1359

2020

Volltextzugriff (PDF)

Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy

Biology of blood and marrow transplantation, 2019-11, Vol.25 (11), p.2113-2123

2019

Volltextzugriff (PDF)

Deconditioning in Stem Cell Transplant Cancer Patients Referred to the “Moving on” Physical Rehabilitation Program

Biology of blood and marrow transplantation, 2017-03, Vol.23 (3), p.S224-S225

2017

Volltextzugriff (PDF)

ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors

Biology of blood and marrow transplantation, 2018-06, Vol.24 (6), p.1119-1124

2018

Volltextzugriff (PDF)

A Retrospective Review of Two Different Antiemetic Regimens for the Prevention of Nausea and Vomiting Associated with High Dose Chemotherapy for Outpatient Autologous Stem Cell Transplantation

Biology of blood and marrow transplantation, 2017-03, Vol.23 (3), p.S284-S284

2017

Volltextzugriff (PDF)

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

The Lancet. Haematology, 2019-09, Vol.6 (9), p.e448-e458

2019

Volltextzugriff (PDF)

Efficacy and safety of venetoclax in combination with azacitidine or decitabine in an outpatient setting in patients with untreated acute myeloid leukemia

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.7044-7044

2022

Volltextzugriff (PDF)

Ublituximab (TG‐1101), a novel glycoengineered anti‐CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial

British journal of haematology, 2017-02, Vol.176 (3), p.412-420

2017

Volltextzugriff (PDF)

Debulking before Initiation of Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Results from a Phase 3b Study

Blood, 2021-11, Vol.138 (Supplement 1), p.3725-3725

2021

Volltextzugriff (PDF)

Treatment Initiation of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in Patients with Untreated Acute Myeloid Leukemia

Blood, 2021-11, Vol.138 (Supplement 1), p.1265-1265

2021

Volltextzugriff (PDF)

Completed Induction Phase Analysis of Magnify: Phase 3b Study of Lenalidomide + Rituximab (R 2) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Blood, 2021-11, Vol.138 (Supplement 1), p.812-812

2021

Volltextzugriff (PDF)

Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy

Transplantation and cellular therapy, 2021-08, Vol.27 (8), p.642-649

2021

Volltextzugriff (PDF)

Lisocabtagene maraleucel (liso-cel) as second-line (2L) therapy for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Primary analysis from the phase 2 PILOT study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.7062-7062

2022

Volltextzugriff (PDF)

Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity Setting: Initial Results from the Outreach Study

Blood, 2020-11, Vol.136 (Supplement 1), p.50-52

2020

Volltextzugriff (PDF)

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in MAGNIFY: A Phase IIIb Interim Analysis of Induction R2 Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Blood, 2020-11, Vol.136 (Supplement 1), p.30-31

2020

Volltextzugriff (PDF)

Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R2 Followed By Maintenance

Blood, 2020-11, Vol.136 (Supplement 1), p.24-25

2020

Volltextzugriff (PDF)

Outreach: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered As Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R/R Large B-Cell Lymphoma (LBCL)

Blood, 2021-11, Vol.138 (Supplement 1), p.1762-1762

2021

Volltextzugriff (PDF)

MAGNIFY phase IIIb interim analysis of induction R 2 followed by maintenance in relapsed/refractory indolent NHL

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.8046-8046

2020

Volltextzugriff (PDF)

1 – 25 von 103

Suche als RSS-Feed

Aktive Filter

ThemaPatients

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(91)
Mit Volltextzugriff
(91)

Publikationsform

Sprache

Englisch
(103)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma

Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single‐arm, phase 2 study

Modified Delphi panel consensus recommendations for management of severe aplastic anemia

Deconditioning after "Moving On" rehabilitation

We will not stop until the world dreams in cheese: Redefining the Wisconsin cheese brand

Leveraging Virtual Reality to Enhance Expeditionary Medical Team Performance in Three Key Areas

Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy

Deconditioning in Stem Cell Transplant Cancer Patients Referred to the “Moving on” Physical Rehabilitation Program

ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors

A Retrospective Review of Two Different Antiemetic Regimens for the Prevention of Nausea and Vomiting Associated with High Dose Chemotherapy for Outpatient Autologous Stem Cell Transplantation

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Efficacy and safety of venetoclax in combination with azacitidine or decitabine in an outpatient setting in patients with untreated acute myeloid leukemia

Ublituximab (TG‐1101), a novel glycoengineered anti‐CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial

Lisocabtagene Maraleucel as Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplant: Final Analysis of the Phase 2 PILOT Study

Debulking before Initiation of Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Results from a Phase 3b Study

Treatment Initiation of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in Patients with Untreated Acute Myeloid Leukemia

Completed Induction Phase Analysis of Magnify: Phase 3b Study of Lenalidomide + Rituximab (R 2) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy

Lisocabtagene maraleucel (liso-cel) as second-line (2L) therapy for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Primary analysis from the phase 2 PILOT study

Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity Setting: Initial Results from the Outreach Study

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in MAGNIFY: A Phase IIIb Interim Analysis of Induction R2 Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R2 Followed By Maintenance

Outreach: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered As Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R/R Large B-Cell Lymphoma (LBCL)

MAGNIFY phase IIIb interim analysis of induction R 2 followed by maintenance in relapsed/refractory indolent NHL

Aktive Filter

Suchergebnisse filtern